Saratov JOURNAL of Medical and Scientific Research

Diagnosis and combined treatment of patients with locally advanced prostate cancer

Year: 2015, volume 11 Issue: №3 Pages: 317-322
Heading: Urology Article type: Review
Authors: Popkov V.M., Kim T.D., Ponukalin A.N.
Organization: Saratov State Medical University

Prostate cancer is one of the most urgent problems of modern oncology. The article provides an overview of the methods of treatment of locally advanced prostate cancer, comparative characteristics, the advantages of both independent and combined methods. The results of multicenter studies have been stated.

1. 1. Aksel' EM. Statistics malignancies in Russia and the CIS in 2008. Vestnik RONC im NN Blohina RAMN 2010; 21 (2), Application 1:160
2. Epidemiology of prostate cancer. In: Matveev BP, ed. Clinical oncourology. A Guide for Physicians. Moscow: Medicine, 2003: 435-440 p.
3. Aksel' ЕМ. Prostate Cancer. Moscow: Medicina, 2002; 1120 p.
4. Ahmedin J, Freddie В, Melissa MC, et al. Global Cancer Statistics. CA: Cancer Journal for Clinicians 2011; 61: 69-90
5. Veliev El. Hormone therapy for prostate cancer. Practical oncology 2008; 9 (2): 98-103
6. Boyle Р, Maisonneuve Р, Napalkov P. Incidence of prostate cancer will double by the year 2030: arguments. Europ J Urol 1996;29:3-9
7. Apolihin Ol, Sivkov AV, Moskaleva NG, Solnceva TV. Analysis of urological morbidity and mortality in the Russian Federation for the ten-year period 2002-2012 years according to official statistics. Experimental and clinical urology 2014; (2): 4-12
8. Zubkov AJu, Ataev RZ. Algorithm for the diagnosis, monitoring and treatment of prostate cancer. In: Topical issues of Urology: Materials jubilee scientific and practical conference devoted to the 100th anniversary of his clinic. A. B. Vishnevsky Kazan, 2000; p. 113-114
9. Veliev El. Hormone therapy for locally advanced and metastatic prostate cancer: current approaches. Practical oncology 2001; 2 (6): 38-41
10. Oncourology: national leadership. М: GJeOTAR-Media, 2012; 688 p.
11. Matveev BP, ed. Diagnosis of prostate cancer. In: Clinical oncourology. monograph for physicians. Moscow: Medicine, 2011: 561-565 p.
12. Pereverzev AC, Kogan Ml. Cancer Prostate. Har'kov, 2004; 231 p.
13. Schnall MD, et al. Prostate cancer:localstading with endorectal surface coil MR imaging. Radiology 1991; 178: 797-802
14. YamadaAH, et al. Results of radical prostatectomy and adjuvant therapy in the management of locally advanced,clinical stage TC, prostate cancer. J Clin Oncol 1994; Aug 17 (4): 277-85
15. Hsu CY, et al. Outcome of surgery for clinical unilateral T3a prostste cancer: a single-institution experience. Eur Urol 2007; 51 (1): 121-8
16. Ward JF, et al. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. В J U Int 2005; 95 (6): 751-756
17. Epstein Jl, CarMichael M, Walsh PS. Adenocarcinoma of the prostate invading the seminal vesicle: definition and relation of tumor volume, grade and margins of resection to prognosis. J Urol 1993; 149: 1040-1046
18. Loran OB, Tomkevich BA. Treatment for prostate cancer in stage T3NxMo. Urology 2004; (6): 5-67
19. Huggins С, Hodges С. Studies on prostate cancer: The effect of castration. Cancer Res 1941; 1: 293-297
20. Prostate cancer. In: Matveeva BP, ed. Clinical oncourology. Moscow: Verdal, 2003; p. 433-606
21. Transrectal color Doppler ultrasonography in patients with prostate cancer before and after orchiectomy. Proceedings of the Board of DOC 1999; 39-40
22. Letkovskaja ТА, Cherstvyj ED, Zaharova VA, Puchinskaja MV Neuroendocrine differentiation in prostate cancer: biological and prognostic value. Medical Journal 2007; 22 (4): 10-12
23. Glybochko PV, Popkov VM. Neuroendocrine aspects of carcinogenesis in the prostate gland. Saratov Journal of Medical Scientific Research 2010; 6 (1): 164-170
24. Kushlinskij NE, Solov'ev JuN, Trapeznikova MF. Prostate Cancer. M., 2002; 432 p.
25. Matveev BP Role casodex 50mg and 150mg in the treatment of advanced prostate cancer: Manual for physicians. M, 2001
26. Karjakin OB. Combined treatment of locally advanced prostate cancer and non-proliferation. In: 3 Materials of the Scientific Conference with the participation of the CIS countries "Actual problems of treatment of diseases oncourological". Moscow, 1999; p. 52-54
27. Arai Y, Yoshika Т, Voshida О. Prognostic significance of prostate specific antigen in endocrine treatment for prostatic cancer. J Urol 1990; 44: 1415-1419
28. Matveeva BP, ed. Clinical oncourology. Moscow: Verdal, 2003; 717 p.
29. Loran OB, Pushkar' DJu, Frank GF. Prostate specific antigen and morphological characteristics of prostate cancer: A Guide for Physicians. Moscow, 1999; 143 p.
30. Matveev BP, Komarova LE, Buharkin BV Resultsof a 5-year screening prostate cancer. Urology 2003; (1): 6-9
31. Aljaev JuG, Aslamazov JeG, Demidko JuL. Hormone therapy for inoperable prostate cancer (the results of their 3-and 5-year observations). In: Materials V-th Russian conference "Actual problems of treatment of cancer", Obninsk, 2003; p. 16
32. Narayan Р, Lowe BA, Carrol P. Neoadjuyant hormonal therapy and radical prostatectomy for clinical stage С carcinoma of the prostate. Br J Urol 1994; (73): 548-554
33. Huggins C, Hodges CV. Studies on prostate cancer I: The effects of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. J Urol2002; 168(1): 9-12
34. Karjakin OB. Standards in the treatment of various stages of prostate cancer. Practical oncology 2001; 2 (6) 24-27
35. Liebel SA, Fuks Z, Zelefsky MJ, et al. The effects of local and regional treatments on the metastatic outcome in prostatic carcinoma with pelvic lymph node involvement. Int J Radiat Oncol Biol Phys 1994; 28 (1): 7-16
36. Horwitz EM, Hanks GE, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008; 26 (15): 2497-2504
37. D Amico AV, Loffredo M, Renshaw AA, et al. Six-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pre-treatment prostate-specific antigen level. J Clin Oncol 2006; 24: 4190-4195
38. Roach M, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long term results of RTOG 8610. J Clin Oncol 2008; 26 (4): 585-591
39. Pilepich MV, Winter K, Roach M, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation before and during radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 50: 1243-1252
40. Roach M, Lawton C, et al. Phase III trial campering whole-pelvic versus prostate-only radiotherapy and neoadjuvant combined androgen suppression: RTOG 9413. J Clinic Oncol 2003; 21 (10): 1904-1911
41. Zagars GK, Pollack A, Smith LG. Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III T3No-xMo adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 1999; 44 (4): 809-819.

2015_03_317-322.pdf298.2 KB

No votes yet